Meeting
2024 ASCO Annual Meeting
A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced NSCLC.
Authors
Chunjiao Wu
Phase I ward, Department of Oncology, Jilin Cancer Hospital, Changchun, Jilin Province, China
Chunjiao Wu , Dongqing Lv , Jiuwei Cui , Zhen Wang , Hui Zhao , Huaxin Duan , Ping Duan , Yongmei Yin , Yueyin Pan , Fu-Nan Liu , Chuize Kong , Jian Zhang , Yongsheng Li , Xinpeng Han , Baogang Liu , Lijie He , Zhiquan Qin , Tao Wu , Mei Ji , Ying Cheng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Biologic Correlates
Clinical Trial Registration Number
NCT05918445
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 8533)
DOI
10.1200/JCO.2024.42.16_suppl.8533
Abstract #
8533
Poster Bd #
397
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase Ib/II study of AK112, a PD-1/VEGF bispecific antibody, as first- or second-line therapy for advanced non–small cell lung cancer (NSCLC).
First Author: Caicun Zhou
Poster
2021 ASCO Annual Meeting
Trial in progress: A phase 1b study of sotorasib, a specific and irreversible KRASG12C inhibitor, as monotherapy in non-small cell lung cancer (NSCLC) with brain metastasis and in combination with other anticancer therapies in advanced solid tumors (CodeBreaK 101).
First Author: David S. Hong
Poster
2021 ASCO Annual Meeting
Camrelizumab monotherapy or in combination with apatinib for PD-L1-positive advanced pulmonary sarcomatoid carcinoma: A multicenter, open-label, single-arm, phase II study.
First Author: Mingfang Zhao
Poster
2018 ASCO Annual Meeting
MORPHEUS: A phase Ib/II multi-trial platform evaluating the safety and efficacy of cancer immunotherapy (CIT)-based combinations in patients (pts) with non-small cell lung cancer (NSCLC).
First Author: Melissa Lynne Johnson